KNSA Kiniksa Pharmaceuticals, Ltd. Stock Quote

KNSA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.58	Insider Own	1.00%	Shs Outstand	68.11M	Perf Week	-3.07%
Market Cap	1.46B	Forward P/E	-	EPS next Y	-2.41	Insider Trans	-31.05%	Shs Float	29.38M	Perf Month	7.52%
Income	-161.40M	PEG	-	EPS next Q	-0.81	Inst Own	95.00%	Short Float	12.90%	Perf Quarter	15.94%
Sales	-	P/S	-	EPS this Y	12.90%	Inst Trans	2.13%	Short Ratio	10.92	Perf Half Y	28.19%
Book/sh	4.58	P/B	4.62	EPS next Y	12.10%	ROA	-52.40%	Target Price	34.00	Perf Year	12.07%
Cash/sh	4.69	P/C	4.51	EPS next 5Y	-	ROE	-57.30%	52W Range	10.30 - 28.67	Perf YTD	19.81%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-24.48%	Beta	-
Dividend %	-	Quick Ratio	10.50	Sales past 5Y	-	Gross Margin	-	52W Low	110.22%	ATR	1.60
Employees	135	Current Ratio	10.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.26	Volatility	7.05% 7.53%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-36.00%	Profit Margin	-	Rel Volume	0.80	Prev Close	21.17
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 24 AMC	Payout	-	Avg Volume	346.92K	Price	21.65
Recom	1.60	SMA20	-0.92%	SMA50	8.14%	SMA200	11.99%	Volume	144,208	Change	2.28%

Jun-29-20

Reiterated

BofA Securities

Buy

$25 → $40

Apr-01-20

Initiated

BofA/Merrill

Buy

$25

Mar-11-19

Initiated

Barclays

Overweight

$26

Dec-12-18

Reiterated

Wedbush

Outperform

$31 → $33

Jun-19-18

Initiated

JMP Securities

Mkt Outperform

$33

Mar-02-21 08:00AM	Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis GlobeNewswire
Feb-28-21 10:54AM	Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Benzinga
Feb-23-21 08:00AM	Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity GlobeNewswire -6.43%
Feb-17-21 04:15PM	3 Top Biotech Stocks With Major Catalysts Approaching TipRanks
Jan-27-21 09:36AM	New Strong Sell Stocks for January 27th Zacks
Jan-11-21 08:00AM	Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones GlobeNewswire
Jan-04-21 04:20PM	Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-20 08:00AM	Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation GlobeNewswire
Dec-18-20 08:51AM	Is KNSA A Good Stock To Buy Now? Insider Monkey
Dec-15-20 08:00AM	Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis GlobeNewswire
Nov-30-20 08:00AM	Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404 GlobeNewswire
Nov-24-20 08:00AM	Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire +9.87%
Nov-23-20 08:00AM	Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis GlobeNewswire
Nov-17-20 08:00AM	Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020 GlobeNewswire
Nov-16-20 08:00AM	Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis GlobeNewswire
Nov-10-20 09:15AM	Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation Simply Wall St.
Nov-09-20 04:01PM	Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data GlobeNewswire
Nov-05-20 07:30AM	Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity GlobeNewswire
Oct-29-20 08:00AM	Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress GlobeNewswire
Oct-26-20 08:00AM	Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020 GlobeNewswire
Oct-14-20 09:54PM	Hedge Funds Are Starting To Get Bullish On Kiniksa Pharmaceuticals, Ltd. (KNSA) Insider Monkey -5.87%
Oct-07-20 10:14AM	Company News for Oct 7, 2020 Zacks
Oct-06-20 08:00AM	Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis GlobeNewswire +18.31%
Sep-24-20 04:12PM	Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th GlobeNewswire
Sep-21-20 08:00AM	Kiniksa Announces Upcoming Rilonacept Analyst Day GlobeNewswire -8.53%
Sep-15-20 08:00AM	Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis GlobeNewswire +5.22%
Sep-09-20 04:01PM	Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire
Aug-31-20 08:00AM	Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020 GlobeNewswire +6.99%
Aug-04-20 08:00AM	Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-30-20 07:30AM	Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity GlobeNewswire
Jul-28-20 03:42PM	Do Insiders Own Lots Of Shares In Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)? Simply Wall St.
Jul-21-20 09:55PM	Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering GlobeNewswire -9.34%
Jul-20-20 04:07PM	Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering GlobeNewswire
Jul-16-20 07:30AM	Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis GlobeNewswire
Jul-08-20 12:53PM	J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels TipRanks
Jul-05-20 11:03PM	Hedge Funds Are Betting On Kiniksa Pharmaceuticals, Ltd. (KNSA) Insider Monkey
Jun-30-20 09:56AM	Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group Zacks
09:35AM	Company News for Jun 30, 2020 Zacks
Jun-29-20 03:47PM	3 Strong Buy Coronavirus Stocks With Massive Upside Potential TipRanks +12.90%
10:48AM	Kiniksa Reports Positive Results of Pericarditis-Drug Trial TheStreet.com
08:09AM	5 Stocks With Recent Price Strength Amid Spike in Coronavirus Zacks
07:15AM	Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) GlobeNewswire
Jun-17-20 08:00AM	Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19 GlobeNewswire
Jun-12-20 10:43AM	Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group Zacks
Jun-10-20 08:00AM	Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts GlobeNewswire +5.16%
Jun-08-20 08:00AM	Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial GlobeNewswire +11.32%
Jun-04-20 08:00AM	Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference GlobeNewswire
May-29-20 08:30AM	Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020 GlobeNewswire
May-22-20 08:56AM	How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry Zacks
May-18-20 04:01PM	Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
May-13-20 11:12PM	Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering GlobeNewswire -10.13%
05:12PM	Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering GlobeNewswire
May-11-20 07:30AM	Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus GlobeNewswire +9.30%
May-06-20 11:43AM	Will Kiniksa Pharmaceuticals Continue to Surge Higher? Zacks
Apr-28-20 07:30AM	Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Apr-22-20 08:00AM	Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint GlobeNewswire
Apr-08-20 11:30AM	Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year? Zacks
Apr-06-20 07:45PM	Coronavirus Stocks Gain: Vir Biotech up 26.6%; Kiniksa off 0.7% TheStreet.com
08:29AM	3 Healthcare Stocks Fighting the Coronavirus TipRanks
Apr-01-20 09:04AM	Company News for Apr 1, 2020 Zacks
Mar-31-20 08:15AM	Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation GlobeNewswire +26.68%
Mar-30-20 07:30AM	Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session GlobeNewswire
Feb-26-20 07:30AM	Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity GlobeNewswire
Feb-11-20 09:12AM	Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance Zacks
Feb-05-20 09:21AM	Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat Zacks
Jan-13-20 08:00AM	Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts GlobeNewswire
Dec-19-19 10:13AM	The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks
Dec-18-19 02:27PM	Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks
Dec-16-19 07:29AM	Did Hedge Funds Drop The Ball On Kiniksa Pharmaceuticals, Ltd. (KNSA) ? Insider Monkey
Dec-12-19 09:59AM	Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy Zacks
Dec-11-19 09:47AM	Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector TipRanks
08:30AM	Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma GlobeNewswire
Dec-10-19 08:00AM	Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire +13.63%
Dec-07-19 07:07AM	We're Keeping An Eye On Kiniksa Pharmaceuticals's (NASDAQ:KNSA) Cash Burn Rate Simply Wall St.
Nov-21-19 10:22AM	Company News For Nov 21, 2019 Zacks
Nov-20-19 04:01PM	Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference GlobeNewswire +28.67%
08:00AM	Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis GlobeNewswire
Nov-16-19 12:00PM	Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Nov-12-19 04:01PM	Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting GlobeNewswire -7.91%
Nov-01-19 10:55AM	Were Hedge Funds Right About Selling Kiniksa Pharmaceuticals, Ltd. (KNSA)? Insider Monkey +5.82%
Oct-28-19 04:01PM	Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Oct-08-19 04:48AM	Kiniksa Pharmaceuticals Enters Oversold Territory Zacks
Sep-19-19 04:01PM	Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research GlobeNewswire
Aug-19-19 07:30AM	Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Aug-12-19 04:02PM	Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
04:01PM	Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial GlobeNewswire
Aug-06-19 07:30AM	Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 07:30AM	Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community GlobeNewswire
Jun-29-19 06:17PM	Is Kiniksa Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ? Insider Monkey
Jun-12-19 07:30AM	Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology GlobeNewswire
Jun-10-19 11:26AM	The Kiniksa Pharmaceuticals (NASDAQ:KNSA) Share Price Is Down 23% So Some Shareholders Are Getting Worried Simply Wall St.
May-30-19 04:01PM	Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019 GlobeNewswire
May-29-19 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
May-16-19 07:30AM	Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research GlobeNewswire
May-13-19 07:30AM	Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology GlobeNewswire
May-02-19 07:30AM	Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Apr-29-19 02:55PM	Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ? Insider Monkey
Apr-23-19 06:00AM	Long-Term "GameChangers" in Biotech MoneyShow
Apr-17-19 04:25PM	Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology GlobeNewswire
Apr-08-19 04:01PM	Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs GlobeNewswire -10.59%

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sanj K	Chairman & CEO	Feb 10	Option Exercise	1.59	1,600	2,544	1,600	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 10	Sale	23.07	1,137	26,231	83,336	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 10	Sale	23.06	1,600	36,896	0	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 09	Option Exercise	1.59	20,401	32,438	20,401	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 09	Sale	23.08	23,569	543,973	84,473	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 09	Sale	23.04	20,401	470,039	0	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 08	Option Exercise	1.59	4,924	7,829	4,924	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 08	Sale	23.00	4,528	104,144	108,042	Feb 10 07:07 PM
Patel Sanj K	Chairman & CEO	Feb 08	Sale	23.00	4,924	113,252	0	Feb 10 07:07 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Feb 03	Sale	22.09	2,477	54,717	297,523	Feb 05 06:55 PM
Patel Sanj K	Chairman & CEO	Oct 12	Option Exercise	1.59	150,700	239,613	150,700	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 12	Sale	21.02	99,330	2,087,917	112,570	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 12	Sale	21.02	150,700	3,167,714	0	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 09	Option Exercise	1.59	872	1,386	872	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 09	Sale	21.00	670	14,070	211,900	Oct 14 05:22 PM
Patel Sanj K	Chairman & CEO	Oct 09	Sale	21.00	872	18,312	0	Oct 14 05:22 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Jul 01	Sale	25.37	29,589	750,678	0	Jul 02 04:13 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Jun 10	Option Exercise	1.59	13,752	21,866	43,341	Jun 12 05:50 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Jun 10	Sale	25.07	13,752	344,763	29,589	Jun 12 05:50 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Apr 21	Sale	19.89	2,518	50,092	29,589	Apr 22 05:39 PM
Beetham Thomas W.	EVP & Chief Legal Officer	Apr 20	Sale	19.06	47,423	903,882	32,107	Apr 22 05:39 PM
Patel Sanj K	Chairman & CEO	Mar 06	Sale	20.00	33,115	662,300	212,570	Mar 10 05:33 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience